Results 91 to 100 of about 25,691 (210)

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta, CODACCI PISANELLI, Giovanni, Colombo, Nicoletta, Cont, Nicoletta Tomasi, D'Alonzo, Marta, Ferrero, Annamaria, Peccatori, Fedro Alessandro   +6 more
core   +3 more sources

Paraneoplastic Lupus Nephritis in a Child With Neuroblastoma Recurrence

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
Gabriele Mortari, Caterina Costagliola, Marta Nebiolo, Francesca Parisi, Martina Morini, Katia Mazzocco, Gabriele Gaggero, Stefano Volpi, Stefania Sorrentino, Virginia Livellara   +9 more
wiley   +1 more source

Topotecan and Ginkgolic Acid Inhibit the Expression and Transport Activity of Human Organic Anion Transporter 3 by Suppressing SUMOylation of the Transporter

Pharmaceutics
Organic anion transporter 3 (OAT3), expressed at the basolateral membrane of kidney proximal tubule cells, facilitates the elimination of numerous metabolites, environmental toxins, and clinically important drugs.
Zhou Yu, Guofeng You
doaj   +1 more source

Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure [PDF]

, 2014
BACKGROUND: Trypanosoma cruzi is the etiological agent of Chagas’ disease that is an endemic disease in Latin America and affects about 8 million people.
Aline Araujo Zuma, Camila Cristina da Silva, Maria Cristina M Motta, Otto Kischlat Lacombe, Wanderley de Souza   +4 more
core   +1 more source

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

BMC Cancer, 2007
Background A platinum doublet is the current standard treatment for good performance status patients with advanced non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status.
Kraft Andrew S, Meyer Mario L, Chaudhary Uzair, Garrett-Mayer Elizabeth, Green Mark R, Sherman Carol A, Beldner Matthew A, Montero Alberto J   +7 more
doaj   +1 more source

Topotecan lacks third space sequestration [PDF]

, 2000
The objective of this study was to determine the influence of pleural and ascitic fluid on the pharmacokinetics of the antitumor camptothecin derivative topotecan.
Gelderblom, A.J. (Hans), Jonge, M.J.A. (Maja) de, Loos, W.J. (Walter), Sparreboom, A. (Alex), Verweij, J. (Jaap)   +4 more
core   +1 more source

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy [PDF]

, 2018
Glioblastoma (GBM) is the most aggressive primary brain tumor and thrives in a microenvironment of relative immunosuppression. The poor clinical outcome of these malignant tumors requires the development of novel treatment options/therapeutic regimens ...
Bernstock, joshua, Gessler, Florian, Peruzzotti Jametti, Luca, Pluchino, S   +3 more
core   +1 more source

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells [PDF]

, 2014
BACKGROUND: Metastatic triple-negative breast cancer is mostly incurable, due to lack of suitable drug targets. The insulin-like growth factor (IGF) system could provide such a target, and IGF-1 receptor (IGF-1R)-directed agents are already available ...
Bonzi, M.C., Craparotta, I., Gariboldi, M.B., Mancini, M., Monti, E., Pagin, M., Taiana, E.   +6 more
core   +2 more sources

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients [PDF]

, 2012
S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. The objective of this study was to characterize the bidirectional pharmacokinetic-pharmacodynamic (PK-PD) interaction between S-CKD602 and monocytes.
Bang YJ, Belani CP, DM, Edwards RP, Friedl, Maruca LJ, Ramalingam S, Ramanathan RK, Stoller RG, Strychor S, Wu H, Zamboni BA, Zamboni WC   +12 more
core   +2 more sources

Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models

Neoplasia: An International Journal for Oncology Research, 2005
To investigate the cellular/molecular basis of the activity of a novel lipophilic camptothecin, gimatecan (ST1481), against slowly proliferating cells, we performed a comparative study of topotecan and gimatecan in human bladder cancer models (HT1376 and
Paola Ulivi, Wainer Zoli, Francesco Fabbri, Giovanni Brigliadori, Luca Ricotti, Anna Tesei, Marco Rosetti, Michelandrea De Cesare, Giovanni L. Beretta, Elisabetta Corna, Rosanna Supino, Franco Zunino   +11 more
doaj   +1 more source